Navigation Links
Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
Date:5/3/2012

uch as glucagon-like peptide-1 (GLP-1) that help regulate blood glucose levels. In addition, LX4211 enhances excretion of glucose in the urine, which may also help to reduce the need for insulin, without causing low blood sugar or hypoglycemia. Lexicon expects to have results from an ongoing Phase 2b trial in type 2 diabetes by mid-year 2012.

About the Clinical Trial in Type 1 Diabetes
The initial Phase 2 proof-of-concept study will be a randomized, double-blinded, placebo-controlled trial in approximately 25 adult patients with type 1 diabetes who will receive LX4211 over a one month treatment period. The primary endpoint of the study will be reduction of insulin required with LX4211 as compared to placebo. Secondary endpoints will include multiple measures of blood sugar to show that LX4211 helps to maintain glycemic control during the treatment period. Under the agreement, additional funding could support future Phase 2 trials of LX4211 in type 1 diabetes.

About Type 1 Diabetes
An estimated 1.3 million people in the U.S. have type 1 diabetes, a chronic disease usually caused by autoimmune destruction of insulin-producing beta cells of the pancreas. The resulting decrease in insulin leads to high levels of glucose in the blood, which in turn can lead to acute metabolic complications as well as chronic problems with eyes, kidneys, nervous system and heart. If not properly controlled with insulin therapy, type 1 diabetes can be fatal. Patients with type 1 diabetes are at least 10 times more at risk for cardiovascular disease compared to people without diabetes. The rate of type 1 diabetes incidence among children under the age of 14 is estimated to increase by 3% annually worldwide.

About Lexicon
Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease. Lexicon currently has five drug programs in mid-stage development for diabetes, carcinoid syndrome, irrita
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
3. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
4. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
5. Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
6. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
7. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
8. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
9. Lexicon Announces Pricing of Common Stock in Public Offering
10. Lexicon Announces Completion of Public Offering of Common Stock
11. Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 Research and Markets  has announced ... 2014-2018" report to their offering. ... is a hollow needle commonly used with a syringe ... extract fluids from it. A hypodermic needle is used ... that cannot be ingested. Hypodermic needles are broadly classified ...
(Date:7/11/2014)... -- On Thursday, July 10, 2014, ... Jones Industrial Average finished the day 0.42% lower at 16,915.07, ... losses were broad based as eight out of ten sectors ... Sector Index ended the day at 711.88, down 0.02%, while ... Investor-Edge has initiated coverage on the following equities: Covidien PLC ...
(Date:7/11/2014)... , July 11, 2014  Veran Medical ... announced today the positive, cost-effective final results ... SPiNPerc™ procedure. The SPiNPerc endobronchial percutaneous biopsy ... percutaneous approach to biopsy when a traditional ... and physicians experience positive financial outcomes when ...
Breaking Medicine Technology:Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4Veran Medical Publishes Lung Cancer Patient Management Study 2
... OAK BROOK, Ill. , July 12 The University ... agreement to Ascent, a leader in health care resource sustainability. The agreement, ... 1, 2010 . Under the contract, Ascent will offer single-use device (SUD) ... , , , ...
... July 12 ( http://www.myprgenie.com ) -- Medrium, Inc., one ... announced it has signed a partnership agreement with RelayHealth to use ... LabCorp and to provide LabCorp results to physicians utilizing the Medrium ... , ...
Cached Medicine Technology:University HealthSystem Consortium Awards Single-Source Agreement to Ascent for Medical Device Reprocessing Services 2University HealthSystem Consortium Awards Single-Source Agreement to Ascent for Medical Device Reprocessing Services 3Medrium Partners With RelayHealth 2Medrium Partners With RelayHealth 3
(Date:7/13/2014)... Recently, iFitDress.com, one of the most famous ... collection of brown evening dresses for worldwide ... at discounted prices, up to 50% off. , ... they are carefully made according to most fashionable styles. ... also offers pretty accessories: wedding shoes, dancing shoes, sandals, ...
(Date:7/13/2014)... variations in the quality of care are the most ... varies widely between regions within Europe, according to the ... date, published in The Lancet Oncology . , ... cancers of the blood has increased over the past ... targeted drugs in the early 2000s such as rituximab ...
(Date:7/13/2014)... research in Nature Genetics identifies a ... that causes eosinophillic esophagitis (EoE), opening up potential ... food allergy. , EoE is a chronic ... triggered by allergic hypersensitivity to certain foods and ... cells called eosinophils (part of the body,s immune ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 Victorian Hotel ... by promoting the rental of bikes for its "Cycle ... downtown Victorian Hotel to tour the area using a ... tax. Bicycle enthusiasts love to call Vancouver home, as ... for cycle travel and picturesque journeys through the countryside. ...
(Date:7/13/2014)... 2014 Advanced boilers are preferred ... amount of fossil fuels, produce high-capacity power, emit ... increased global warming and climate change concerns, many ... harmful gas emissions and pollutants coming from fossilfuel-based ... the global advance boilers market., The global power ...
Breaking Medicine News(10 mins):Health News:2014 Brown Evening Dresses Added To iFitDress.com 2Health News:The Lancet Oncology: Differences in treatment likely to be behind differing survival rates for blood cancers between regions within Europe 2Health News:The Lancet Oncology: Differences in treatment likely to be behind differing survival rates for blood cancers between regions within Europe 3Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 2Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 3Health News:Victorian Hotel Creates Excitement by Adding "Cycle the City" Bike Rentals for Its Vancouver Hotel Rooms 2Health News:North America Advanced Boilers Market is Expected to Reach $518.7billion by 2019 - New Report by MicroMarket Monitor 2Health News:North America Advanced Boilers Market is Expected to Reach $518.7billion by 2019 - New Report by MicroMarket Monitor 3
... Brain Center America,s New Neuroactive Exercise Bike Trains the Body and Brain ... ... Fitness centers are entering the next lap of their evolution with the ... body and the brain as a joint fitness program , Stephane Bergeron, ...
... Holdings Inc.,(OTC Bulletin Board: CLXS), a leading developer ... that their life science research,portal http://www.BiomedExperts.com ... in December has exploded to over 60,000 per ... , (Logo: ...
... Inc., the nation,s largest independent behavioral health care ... an agreement with CareIntegra to provide enhanced integrated ... product offerings. (Logo: http://www.newscom.com/cgi-bin/prnh/20090106/PH55551LOGO ... ValueOptions(R) will collaborate to develop and conduct a ...
... TV Teacher, LLC(TM) announces the,donation of their video-modeling programs ... Bronx, and Staten Island. , ... Ellis, a mother struggling to help her frustrated five-year-old ... an unsuccessful two years of,"traditional" therapy, she realized she ...
... Pharmaceutical,Inc. (Nasdaq: BMRN ) today announced that ... company update at the 27th,Annual J.P. Morgan Healthcare Conference ... a.m. PT. , Interested parties ... call,via the investor section of the BioMarin website, ...
... Jan. 7 Atlanta-based Billian Publishing, Inc.,owners of ... , (Logo: ... Porter Research was founded in 1989 just as ... of accelerated innovation. Since then, new,and established companies ...
Cached Medicine News:Health News:Neuroactive Bike: America's First And Only Mind-Body Fitness Equipment Used For The Ultimate Brain Fitness Gym Program Launched This Month At Lady Of America Fitness Center 2Health News:Neuroactive Bike: America's First And Only Mind-Body Fitness Equipment Used For The Ultimate Brain Fitness Gym Program Launched This Month At Lady Of America Fitness Center 3Health News:Neuroactive Bike: America's First And Only Mind-Body Fitness Equipment Used For The Ultimate Brain Fitness Gym Program Launched This Month At Lady Of America Fitness Center 4Health News:Collexis BiomedExperts Hits 80,000 Registered Users Within the First Year! 2Health News:Collexis BiomedExperts Hits 80,000 Registered Users Within the First Year! 3Health News:ValueOptions(R) Enters Agreement with CareIntegra to Provide Integrated Health Services 2Health News:New York Schools Receive Program for Children with Autism 2Health News:BioMarin to Present at the 27th Annual J.P. Morgan Healthcare Conference 2Health News:Billian Publishing, Inc. Announces Acquisition of Porter Research 2
CRP Liquid Conrtols level 3...
Therapeutic Drug Calibrator Series...
The IRN method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of iron in serum....
The AST method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of aspartate aminotransferase activity in serum or plasma...
Medicine Products: